Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study (Annals of Hematology, (2024), 10.1007/s00277-024-05958-8)

Weijun Fu; Soo Mee Bang; Honghui Huang; Kihyun Kim; Wei Li; Gang An; Je Jung Lee; Zhen Cai; Jie Jin; Yafei Wang; Chor Sang Chim; Robin Carson; Rui Liu; Man Zhao; Xi Chen; Canchan Cui; Jian Hou; Jianxiang Wang

doi:10.1007/s00277-024-06020-3

Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study (Annals of Hematology, (2024), 10.1007/s00277-024-05958-8)

Weijun Fu
, Soo Mee Bang
, Honghui Huang
, Kihyun Kim
, Wei Li
, Gang An
, Je Jung Lee
, Zhen Cai
, Jie Jin
, Yafei Wang
, Chor Sang Chim
, Robin Carson
, Rui Liu
, Man Zhao
, Xi Chen
, Canchan Cui
, Jian Hou
, Jianxiang Wang

Department of Internal Medicine

Research output: Contribution to journal › Comment/debate

Abstract

https://doi.org/10.1007/s00277-024-05958-8. The article “Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Studyl”, written by Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Man Zhao, Xi Chen, Canchan Cui, Jian Hou and Jianxiang Wang, was originally published Online First without Open Access. After publication, the author decided to opt for Open Choice and to make the article an Open Access publication.

Original language	English
Pages (from-to)	4835-4836
Number of pages	2
Journal	Annals of Hematology
Volume	103
Issue number	11
DOIs	https://doi.org/10.1007/s00277-024-06020-3
State	Published - Nov 2024

Access to Document

10.1007/s00277-024-06020-3

Fingerprint

Dive into the research topics of 'Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study (Annals of Hematology, (2024), 10.1007/s00277-024-05958-8)'. Together they form a unique fingerprint.

Cite this

Fu, W., Bang, S. M., Huang, H., Kim, K., Li, W., An, G., Lee, J. J., Cai, Z., Jin, J., Wang, Y., Chim, C. S., Carson, R., Liu, R., Zhao, M., Chen, X., Cui, C., Hou, J., & Wang, J. (2024). Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study (Annals of Hematology, (2024), 10.1007/s00277-024-05958-8). Annals of Hematology, 103(11), 4835-4836. https://doi.org/10.1007/s00277-024-06020-3

Fu, Weijun ; Bang, Soo Mee ; Huang, Honghui et al. / Correction to : Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study (Annals of Hematology, (2024), 10.1007/s00277-024-05958-8). In: Annals of Hematology. 2024 ; Vol. 103, No. 11. pp. 4835-4836.

@article{b02104c7ab19435a89adcfdd04f3f6d3,

title = "Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study (Annals of Hematology, (2024), 10.1007/s00277-024-05958-8)",

abstract = "https://doi.org/10.1007/s00277-024-05958-8. The article “Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Studyl”, written by Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Man Zhao, Xi Chen, Canchan Cui, Jian Hou and Jianxiang Wang, was originally published Online First without Open Access. After publication, the author decided to opt for Open Choice and to make the article an Open Access publication.",

author = "Weijun Fu and Bang, \{Soo Mee\} and Honghui Huang and Kihyun Kim and Wei Li and Gang An and Lee, \{Je Jung\} and Zhen Cai and Jie Jin and Yafei Wang and Chim, \{Chor Sang\} and Robin Carson and Rui Liu and Man Zhao and Xi Chen and Canchan Cui and Jian Hou and Jianxiang Wang",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = nov,

doi = "10.1007/s00277-024-06020-3",

language = "English",

volume = "103",

pages = "4835--4836",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "11",

}

Fu, W, Bang, SM, Huang, H, Kim, K, Li, W, An, G, Lee, JJ, Cai, Z, Jin, J, Wang, Y, Chim, CS, Carson, R, Liu, R, Zhao, M, Chen, X, Cui, C, Hou, J & Wang, J 2024, 'Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study (Annals of Hematology, (2024), 10.1007/s00277-024-05958-8)', Annals of Hematology, vol. 103, no. 11, pp. 4835-4836. https://doi.org/10.1007/s00277-024-06020-3

Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study (Annals of Hematology, (2024), 10.1007/s00277-024-05958-8). / Fu, Weijun; Bang, Soo Mee; Huang, Honghui et al.
In: Annals of Hematology, Vol. 103, No. 11, 11.2024, p. 4835-4836.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study (Annals of Hematology, (2024), 10.1007/s00277-024-05958-8)

AU - Fu, Weijun

AU - Bang, Soo Mee

AU - Huang, Honghui

AU - Kim, Kihyun

AU - Li, Wei

AU - An, Gang

AU - Lee, Je Jung

AU - Cai, Zhen

AU - Jin, Jie

AU - Wang, Yafei

AU - Chim, Chor Sang

AU - Carson, Robin

AU - Liu, Rui

AU - Zhao, Man

AU - Chen, Xi

AU - Cui, Canchan

AU - Hou, Jian

AU - Wang, Jianxiang

PY - 2024/11

Y1 - 2024/11

N2 - https://doi.org/10.1007/s00277-024-05958-8. The article “Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Studyl”, written by Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Man Zhao, Xi Chen, Canchan Cui, Jian Hou and Jianxiang Wang, was originally published Online First without Open Access. After publication, the author decided to opt for Open Choice and to make the article an Open Access publication.

AB - https://doi.org/10.1007/s00277-024-05958-8. The article “Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Studyl”, written by Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Man Zhao, Xi Chen, Canchan Cui, Jian Hou and Jianxiang Wang, was originally published Online First without Open Access. After publication, the author decided to opt for Open Choice and to make the article an Open Access publication.

UR - https://www.scopus.com/pages/publications/85204639616

U2 - 10.1007/s00277-024-06020-3

DO - 10.1007/s00277-024-06020-3

M3 - Comment/debate

C2 - 39311958

AN - SCOPUS:85204639616

SN - 0939-5555

VL - 103

SP - 4835

EP - 4836

JO - Annals of Hematology

JF - Annals of Hematology

IS - 11

ER -

Fu W, Bang SM, Huang H, Kim K, Li W, An G et al. Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study (Annals of Hematology, (2024), 10.1007/s00277-024-05958-8). Annals of Hematology. 2024 Nov;103(11):4835-4836. doi: 10.1007/s00277-024-06020-3

Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study (Annals of Hematology, (2024), 10.1007/s00277-024-05958-8)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this